Q: Received my first dividend on this US listed stock in my US Rif. After looking at all the dividends in and deductions out, I calculate I'm paying approx. 47% with holding tax! 37% appears to be on the US side, 10% on the Canadian side. Sound about right to you? If so I'll be selling this right quick!
Also, do I now have to worry about filing US taxes?
Palantir’s accounts receivable (AR) is first up. The traditional metric for AR is Days Sales Outstanding (DSO), with higher DSO implying customers are taking their time to pay for Palantir’s services for one reason or another.
In 9 of the last 12 quarters, AR grew faster than revenue – a persistent pattern generally attached to nefarious tricks such as channel stuffing, aggressive revenue recognition, or extended payment terms used as sales concessions. For real subscription businesses, AR growth should track revenue growth closely. When AR is volatile or outgrows revenue, it means the company is booking sales faster than it is collecting cash.
Q: I must be missing something re MU. It is trading aa bit over 10x next years earnings, unless my sources are wrong. My question is why? They are building two new huge production facitilites in Boise, one in Japan and one in New York, because the supply can't keep up with demand. Their margins have increased from around 15% 18 months ago to 55% now, and they are projecting 66% in Q1.
I know they have two major (successful) competitors, but the demand is so strong, and the backlogs so long, I just don't see any major risk for at least the next 12-18 months. Am I wrong? So why is the PE so low?
Paul Krugman recently wrote the following in a Substack post:
'And the damage from the assault on vaccines continues to widen. Last week the Food and Drug Administration refused to review Moderna’s new mRNA-based flu vaccine. They didn’t reject it based on evidence; they wouldn’t even look at it, in line with RFK Jr.’s evidence-free, dogmatic assertion that mRNA technology, which gave us Covid vaccines, is useless and harmful. Pharmaceutical companies, understandably, are retreating from vaccine development.'
Is this another reason to avoid, or to at least reduce exposure to companies involved in vaccine development? For those of us with ETFs in the Health Care Sector, this becomes a daunting task.
Personally, I can't wait until the US midterms so that hopefully there can be some hope that this madness will end.
Q: Hello Team and good Family Day for the ones in Ontario,
Apart from the market fixation now on overspending on AI which costs a bundle and may not generate more profit, I read somewhere an analyst making a parallel between GE (pre-separation in 3 separate entities) and the 3 members of the Mag 7 listed above. He says they may be going the way GE did when the market started pricing conglomerates the way it did for the last 15 years which consequently brought GE to a very low multiple. What did it for GE, he says, was being involved in different and unrelated businesses, for one, and one strong entity pulling the weight of costly money losing members for another. He says it is also true especially in the AMZN and GOOG cases. What do you think? As always thanks for your strong insight, Adel.
Q: Their latest acquisition seemed to be a good move into the drone data recovery space and with their latest earnings growth and strong business model (eg. getting paid their subscriptions for the gov't upfront to provide upfront cash) and growing focus on non-government areas (eg. military or private sector w/ the Corellium acquisition) what am I missing with this company? Why are investors staying away and creating such volatility when results are good.
Q: I just sold a position in Regeneron, and I am looking to replace it with another name in the healthcare space. I already hold ISRG, but I am reticent to add to it while it seems to trade sideways. Lilly has performed well, but I am unsure if it is now fully valued.A recent interviewee on CNBC had mentioned Amgen and Gilead as names which could do well. Any suggestions for names to consider in the healthcare space? I’d be okay with both Canadian and US names. Thanks so much, and I look forward to your response.
Q: Greetings 5i, do you see any positives for this company? I know 5i does not place much weight on analyst ratings but the TMX website shows 7 analysts, 1 buy/6 hold ratings, targets range from $7 - $9. Thank you for your insights on this one.